Goldman Sachs is contemplating improving the conditions on $1.73 billion in leveraged loans associated with chemical manufacturer Arclin's purchase of DuPont's Aramids division. Bloomberg posted on X, indicating that the financial institution is assessing potential adjustments to make the loan package more appealing to investors. The acquisition, which involves a significant financial commitment, has prompted Goldman to explore options that could facilitate the transaction and ensure its success in the market. The move comes amid a competitive landscape in the chemical industry, where strategic acquisitions are crucial for growth and expansion. As Goldman Sachs reviews the loan terms, the focus remains on aligning the financial structure with market expectations and investor interests.